EA201592020A1 - Новая композиция для неалкогольной жировой болезни печени (нажбп) - Google Patents

Новая композиция для неалкогольной жировой болезни печени (нажбп)

Info

Publication number
EA201592020A1
EA201592020A1 EA201592020A EA201592020A EA201592020A1 EA 201592020 A1 EA201592020 A1 EA 201592020A1 EA 201592020 A EA201592020 A EA 201592020A EA 201592020 A EA201592020 A EA 201592020A EA 201592020 A1 EA201592020 A1 EA 201592020A1
Authority
EA
Eurasian Patent Office
Prior art keywords
nafld
liver disease
fatial
nonalcoholic
new composition
Prior art date
Application number
EA201592020A
Other languages
English (en)
Russian (ru)
Inventor
Панкадж Пател
Раджендракумар Харипрасад Джани
Original Assignee
Кадила Хелзкэр Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кадила Хелзкэр Лимитед filed Critical Кадила Хелзкэр Лимитед
Publication of EA201592020A1 publication Critical patent/EA201592020A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA201592020A 2013-04-22 2013-06-25 Новая композиция для неалкогольной жировой болезни печени (нажбп) EA201592020A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1468MU2013 IN2013MU01468A (2) 2013-04-22 2013-06-25
PCT/IN2013/000391 WO2014174524A1 (en) 2013-04-22 2013-06-25 A novel composition for nonalcoholic fatty liver disease (nafld)

Publications (1)

Publication Number Publication Date
EA201592020A1 true EA201592020A1 (ru) 2016-05-31

Family

ID=49253372

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201592020A EA201592020A1 (ru) 2013-04-22 2013-06-25 Новая композиция для неалкогольной жировой болезни печени (нажбп)

Country Status (21)

Country Link
US (3) US20160166539A1 (2)
EP (1) EP2988736A1 (2)
JP (1) JP6246895B2 (2)
KR (1) KR101617812B1 (2)
CN (1) CN105377246B (2)
AP (1) AP2015008674A0 (2)
AU (1) AU2013387996B2 (2)
BR (1) BR112015020600A2 (2)
CA (1) CA2900435C (2)
EA (1) EA201592020A1 (2)
GE (1) GEP201706663B (2)
HK (1) HK1214968A1 (2)
IL (2) IL240183A (2)
IN (1) IN2013MU01468A (2)
MA (1) MA38385A1 (2)
MX (1) MX346943B (2)
MY (1) MY180160A (2)
PH (1) PH12015501795A1 (2)
SG (1) SG11201506218UA (2)
UA (1) UA114360C2 (2)
WO (1) WO2014174524A1 (2)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3009136A1 (en) 2011-01-31 2016-04-20 Cadila Healthcare Limited Treatment for lipodystrophy
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
IN2013MU01468A (2) 2013-04-22 2015-04-17 Cadila Healthcare Ltd
PH12015502667B1 (en) 2013-05-30 2023-10-18 Zydus Lifesciences Ltd A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities
TW201636015A (zh) * 2013-07-05 2016-10-16 卡地拉保健有限公司 協同性組成物
IN2013MU02470A (2) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
IN2013MU02905A (2) 2013-09-06 2015-07-03 Cadila Healthcare Ltd
WO2017064635A2 (en) 2015-10-14 2017-04-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
EP3445363A1 (en) * 2016-04-22 2019-02-27 Taiwanj Pharmaceuticals Co., Ltd. Nalmefene, naltrexone or derivatives thereof for use in treating (non)-alcoholic steatohepatitis or non-alcoholic fatty liver disease
BR112019011740A2 (pt) 2016-12-09 2019-10-29 Cadila Healthcare Limited composição farmacêutica e método para o tratamento de colangite biliar primária
PT3600309T (pt) 2017-03-28 2022-10-03 Gilead Sciences Inc Combinações terapêuticas para o tratamento de doenças hepáticas
GB201710229D0 (en) * 2017-06-27 2017-08-09 Tdeltas Ltd Compounds for new use
KR102419458B1 (ko) 2017-10-06 2022-07-12 길리애드 사이언시즈, 인코포레이티드 Acc 억제제를 포함하는 조합 요법
CN109675016A (zh) * 2017-10-18 2019-04-26 上海贺普药业股份有限公司 非酒精性脂肪性肝病的治疗药物
CN110934866B (zh) * 2018-09-25 2023-12-01 深圳微芯生物科技股份有限公司 西格列羧及其相关化合物的应用
US12201609B2 (en) * 2018-12-18 2025-01-21 Zydus Lifesciences Limited Saroglitazar for the treatment of hepatocellular carcinoma
WO2020165782A1 (en) * 2019-02-13 2020-08-20 Cadila Healthcare Limited Treatment for polycystic ovarian syndrome (pcos)
CN116546981A (zh) * 2020-12-18 2023-08-04 雀巢产品有限公司 使用至少一种甘氨酸或其衍生物和/或至少一种n-乙酰半胱氨酸或其衍生物以及至少一种百里酚和/或香芹酚的组合物和方法
US20220378786A1 (en) * 2021-05-21 2022-12-01 HepQuant, LLC Methods of defining functional change and slowing progression in chronic liver disease
WO2025238663A1 (en) * 2024-05-16 2025-11-20 Zydus Lifesciences Limited Saroglitazar for the treatment of alcoholic liver diseases

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
MX7065E (es) 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
CA2139442A1 (en) 1992-07-03 1994-01-20 David Haigh Heterocyclic compounds as pharmaceutical
GB9225386D0 (en) 1992-12-04 1993-01-27 Smithkline Beecham Plc Novel compounds
US5387613A (en) 1993-07-23 1995-02-07 Ribogene, Inc. Treatment of tachyarrhythmias of supraventricular origin
GB9326171D0 (en) 1993-12-22 1994-02-23 Smithkline Beecham Plc Novel compounds
WO1996004261A1 (en) 1994-07-29 1996-02-15 Smithkline Beecham Plc Benzoxazoles and pryridine derivatives useful in the treatment of the type ii diabetes
EP0826688B1 (en) 1995-04-28 2001-09-05 Daiichi Pharmaceutical Co., Ltd. Pentacyclic compounds
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
CN1280574A (zh) 1997-10-27 2001-01-17 雷迪研究基金会 新的杂环化合物及其在医药中的应用、它们的制备方法和含有它们的药物组合物
WO1999019313A1 (en) 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
ATE286032T1 (de) 1998-04-23 2005-01-15 Reddys Lab Ltd Dr Heterozyklische verbindungen,und deren verwendung in arzneimittel,verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
JP2002507543A (ja) 1998-05-27 2002-03-12 ドクター・レディーズ・リサーチ・ファウンデーション 二環系化合物、その製造方法およびそれらを含有する薬学的組成物
JP2002527503A (ja) 1998-10-21 2002-08-27 ノボ ノルディスク アクティーゼルスカブ 新規化合物類、それらの調製及び使用
AU6325599A (en) 1998-10-21 2000-05-08 Dr. Reddy's Research Foundation New compounds, their preparation and use
WO2000023451A1 (en) 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
ES2449194T3 (es) 2000-01-19 2014-03-18 Cadila Healthcare Limited Compuestos que tienen actividades hipolipidémica e hipocolesterolémica, procedimiento para su preparación y composiciones farmacéuticas que los contienen
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
AU2001286163A1 (en) 2000-09-22 2002-04-02 Dr. Reddy's Research Foundation An improved process for the preparation of 3-aryl-2-hydroxy propanoic acid derivatives
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US6987123B2 (en) * 2001-07-26 2006-01-17 Cadila Healthcare Limited Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20070051626A1 (en) 2003-09-26 2007-03-08 Chiho Itou Cataphoresis apparatus cataphoresis method, and detection method for organism-related material using the apparatus and the method
CN102127057A (zh) 2004-03-15 2011-07-20 武田药品工业株式会社 二肽基肽酶抑制剂
WO2007035771A2 (en) * 2005-09-19 2007-03-29 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Modulation of glucagon receptor expression
AU2007297388A1 (en) * 2006-09-18 2008-03-27 Alnylam Pharmaceuticals, Inc. RNAi modulation of scap and therapeutic uses thereof
JP2008184429A (ja) * 2007-01-30 2008-08-14 Japan Health Science Foundation 肝臓トリグリセリド濃度低下剤
EA020849B1 (ru) 2009-11-26 2015-02-27 Женфит Применение 1,3-дифенилпроп-2-ен-1-оновых производных для лечения заболеваний печени
EP2627323A4 (en) 2010-10-12 2014-03-12 Univ Johns Hopkins HUSTENSTILLENDE COMPOSITIONS WITH MEMANTINE
EP3009136A1 (en) * 2011-01-31 2016-04-20 Cadila Healthcare Limited Treatment for lipodystrophy
IN2013MU01468A (2) 2013-04-22 2015-04-17 Cadila Healthcare Ltd
PH12015502667B1 (en) 2013-05-30 2023-10-18 Zydus Lifesciences Ltd A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities
TW201636015A (zh) 2013-07-05 2016-10-16 卡地拉保健有限公司 協同性組成物
IN2013MU02470A (2) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
US9951009B2 (en) 2013-08-29 2018-04-24 Cadila Healthcare Limited Polymorphic form of pyrrole derivative and intermediate thereof
IN2013MU02905A (2) 2013-09-06 2015-07-03 Cadila Healthcare Ltd

Also Published As

Publication number Publication date
US20160166539A1 (en) 2016-06-16
IL240183A0 (en) 2015-09-24
MX346943B (es) 2017-04-06
US9814697B2 (en) 2017-11-14
WO2014174524A1 (en) 2014-10-30
US20180185330A1 (en) 2018-07-05
KR20150118990A (ko) 2015-10-23
AP2015008674A0 (en) 2015-08-31
AU2013387996A1 (en) 2015-09-24
CA2900435A1 (en) 2014-10-30
IL247231A (en) 2017-03-30
EP2988736A1 (en) 2016-03-02
IN2013MU01468A (2) 2015-04-17
WO2014174524A8 (en) 2015-10-01
CN105377246A (zh) 2016-03-02
US20170087127A1 (en) 2017-03-30
CA2900435C (en) 2017-02-14
MY180160A (en) 2020-11-23
IL240183A (en) 2016-08-31
UA114360C2 (uk) 2017-05-25
KR101617812B1 (ko) 2016-05-03
MX2015010769A (es) 2015-11-26
BR112015020600A2 (pt) 2017-07-18
HK1214968A1 (zh) 2016-08-12
AU2013387996B2 (en) 2015-12-10
JP6246895B2 (ja) 2017-12-13
SG11201506218UA (en) 2015-09-29
JP2016515608A (ja) 2016-05-30
MA38385A1 (fr) 2017-09-29
PH12015501795A1 (en) 2015-11-09
GEP201706663B (en) 2017-05-10
CN105377246B (zh) 2018-03-20

Similar Documents

Publication Publication Date Title
EA201592020A1 (ru) Новая композиция для неалкогольной жировой болезни печени (нажбп)
MX360979B (es) Composiciones de galacto-ramnogalacturonato para el tratamiento de la esteatohepatitis no alcohólica y de la enfermedad del higado graso no alcohólico.
MX2019005082A (es) Composiciones que comprenden 15-ohepa y metodos para usar las mismas.
JO3686B1 (ar) جلوكان ومركبات مساعِدات glp-1 مشتركة
UA118255C2 (uk) Композиція, яка містить антитіло до cd38 і леналідомід
MX2016013049A (es) Inhibidores de autotaxina espirociclicos sustituidos.
EA201790124A1 (ru) Соли берберина, соли урсодезоксихолевой кислоты и их комбинации, способы получения и применения
MX373872B (es) Composiciones de isoxazolina y uso de las mismas en la prevención o tratamiento de infestaciones parasitarias en animales.
EA201390085A1 (ru) Композиции ингибиторов киназ для лечения рака
EA201290919A1 (ru) Индазольные соединения и их применение
MX349159B (es) Derivados deuterados de ivacaftor.
EA201791770A1 (ru) Фармацевтические композиции для комбинированной терапии
BR112015022197A2 (pt) tratamento de cataplexia
MX2014004074A (es) Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2.
MD20140136A2 (ro) Inhibitori ai virusului hepatic C
MX2021002305A (es) Tratamiento de trastornos del higado.
BR112013021566A2 (pt) composto de fórmula, ou um aduto ou sal farmaceuticamente aceitável do mesmo e método de prevenção e/ou tratamento de um indivíduo que compreende a administração ao dito indivíduo uma quantidade terapeuticamente eficaz de um composto de fórmula
EA201890898A1 (ru) Новые соединения и конъюгаты криптофицина, их получение и их терапевтическое применение
BR112016024020A2 (pt) composição farmacêutica
EA201491500A1 (ru) Способы лечения фиброза
PL423259A1 (pl) Koniugaty przeciwciało-ureaza dla celów terapeutycznych
EA201790253A1 (ru) Ингибиторы альдостеронсинтазы
MX2012012095A (es) Analogos de tiazolidinadiona.
EA201791365A1 (ru) Замещенный пиридил-циклоалкил-карбоновые кислоты, содержащие их композиции и их медицинское применение
MX2019002579A (es) Composiciones y metodos de uso de depuradores de gamma-cetoaldehido para tratar, evitar o mejorar la enfermedad del higado graso no alcoholico (nafld), nash, ald o condiciones relacionadas al higado.